Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.4052W HIGH $9.89
Volume
8.16 M
Value Traded
32.36 M
Short % Float
17.78%
Days to Cover
8.2
+36.38%Week
+50.09%1 Month
+27.4%3 Month
+28.36%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.55 B
EPS (TTM)
-0.85
P/E Ratio
-
Ent. Value
696.22 M
Total Shares
181.68 M
Float Shares
180.37 M
Insiders
0.72%
Institutions
86.55%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TDOC Catalyst Timeline
Dated clinical, regulatory and corporate events for Teladoc Health, Inc.
Past FDA Catalysts and PDUFA Decisions
How TDOC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Teladoc Health, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every TDOC program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Catapano Joseph RonaldOfficer (Chief Accounting Officer) | Sell | -655 14,293 held | $5.65 | 10/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TDOC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0.5 % (25 %) | 9.80 M | 1.40 M |
TDOC Institutional Ownership Trends
TDOC Short Interest
Shares sold short, counted twice a month.
17.78%
Short % of Float
of tradable shares sold short
32.1M
Shares Sold Short
+6.5% vs prior count
8.2 High
Days to Cover
trading days of normal volume to buy every short share back
3.9M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TDOC ranks across every disease it competes in
Competitive Position is a premium feature
See how TDOC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTDOC News
-TDOC
Oct 28, 2026▲ +26.9%on this news
Teladoc Health Reports Third Quarter 2026 Results
Teladoc Health reported its third quarter 2026 results, revealing a 3% decline in revenue to $605.1 million and a net loss of $26.9 million. The Integrated Care segment saw a 2% revenue increase, while the BetterHelp segment experienced a 13% decrease. Adjusted EBITDA rose by 14%, indicating improved operational efficiency.
Read more →-TDOC
Oct 14, 2026Teladoc Health to Announce Third Quarter 2026 Financial Results
Teladoc Health Inc. will announce its third quarter 2026 financial results on October 28, 2026, after market close. A conference call to review these results will take place at 5:00 p.m. ET on the same day. Participants can join via phone or a live audio webcast, with a replay available afterward.
Read more →-TDOC
Oct 7, 2026Teladoc Health Expands Solo Connected Care Platform with AI-Powered Capabilities to Help Hospitals Scale Smarter Care Delivery
Teladoc Health has expanded its Solo connected care platform by introducing two AI-powered features, SoloVitals and SoloScribe. These innovations aim to enhance patient care by providing timely insights and reducing technology fragmentation. SoloVitals enables contactless vital sign measurements, while SoloScribe automates clinical documentation, allowing clinicians to focus more on patient interactions. Both features are designed to improve efficiency and scalability in healthcare delivery.
Read more →-TDOC
Sep 25, 2026Teladoc Health Announces Chief Legal Officer Transition
Teladoc Health has announced a leadership transition, with Adam Vandervoort resigning as Chief Legal Officer effective November 1, 2026. Jonathan Dorfman, currently Senior VP of Securities and Corporate Law, will succeed him on November 2, 2026. Vandervoort's tenure included significant milestones for the company, while Dorfman brings valuable experience from his previous roles.
Read more →-TDOC
Sep 3, 2026Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08
Teladoc Health has announced the issuance of employee inducement awards to Michael Grasher, who will serve as the new Chief Financial Officer starting September 1, 2026. The awards include restricted stock units and performance stock units tied to the company's financial performance. This move is part of Teladoc's strategy to attract top talent and align their interests with company growth.
Read more →-TDOC
Aug 31, 2026Teladoc Health Appoints Michael Grasher as Chief Financial Officer
Teladoc Health has appointed Michael Grasher as Chief Financial Officer, effective immediately. Grasher, who has over three decades of experience in finance, previously held CFO roles at various companies, including IFG Companies and Fortegra. His expertise is expected to enhance Teladoc's strategic execution and operational discipline, contributing to the company's growth objectives.
Read more →-TDOC
Aug 3, 2026Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors
Teladoc Health has appointed Mark V. Anquillare to its board of directors. Anquillare, who has over 30 years of financial leadership experience, previously served as president and COO of Verisk Analytics. His background in data and technology is expected to support Teladoc's growth and innovation in virtual care.
Read more →-TDOC
Jul 29, 2026▼ -28.3%on this newsshared move
Teladoc Health Reports Second Quarter 2026 Results
Teladoc Health reported its financial results for the second quarter of 2026, revealing a 4% decrease in revenue year-over-year, totaling $606.9 million. The company experienced a net loss of $38.9 million, compared to a loss of $32.7 million in the same quarter last year. While the Integrated Care segment showed slight revenue growth, the BetterHelp segment faced significant declines, prompting adjustments to revenue outlooks for the remainder of the year.
Read more →-TDOC
Jul 27, 2026Teladoc Health Canada Achieves Accreditation Canada Primer Award, Advancing Quality Standards for Virtual and Hybrid Care in Canada
Teladoc Health Canada has been awarded the Accreditation Canada Primer Award, recognizing its dedication to providing safe and high-quality virtual and hybrid care. This accolade positions Teladoc as a leader in evaluating clinical quality and patient safety in innovative care models. The award highlights the importance of accreditation in enhancing healthcare standards.
Read more →-TDOC
Jul 23, 2026Teladoc Health introduces a virtual care practice built around the person, shaping a new era of connected care
Teladoc Health has launched Teladoc One, a new model of virtual care designed to provide personalized and connected healthcare experiences. This approach aims to address the challenges of fragmented care by utilizing multidisciplinary teams and AI support to adapt to individual patient needs. The initiative is set to improve health outcomes while reducing overall care costs, with plans for broader implementation in 2027.
Read more →-TDOC
Jul 15, 2026Teladoc Health to Announce Second Quarter 2026 Financial Results
Teladoc Health Inc. will announce its second quarter 2026 financial results on July 29, 2026, after market close. A conference call will follow at 5:00 p.m. ET to discuss the results. Participants can access the call via phone or a live audio webcast. A replay will be available for 90 days post-call.
Read more →-TDOC
Jul 3, 2026Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08
Teladoc Health has announced the issuance of an inducement award to David Packles, the new Head of Product at BetterHelp. Effective July 1, 2026, Packles received 50,000 restricted stock units, which will vest over three years. This award was approved by the Compensation Committee and aligns with NYSE Rule 303A.08.
Read more →-TDOC
May 28, 2026▲ +14%on this news
Teladoc Health Expands Access to Care Through Walmart’s Better Care Services
Teladoc Health has partnered with Walmart to offer its virtual care services through Walmart's Better Care Services platform. This collaboration aims to provide convenient and affordable healthcare options, including urgent care, dermatology, and nutrition services. Customers can access these services for a cash-pay price of $89 per visit, enhancing care accessibility for millions of Americans.
Read more →-TDOC
Apr 29, 2026Teladoc Health Reports First Quarter 2026 Results
Teladoc Health reported its financial results for the first quarter of 2026, revealing a 2% decrease in revenue year-over-year, totaling $613.8 million. The company experienced a net loss of $63.8 million, although it reaffirmed its full-year financial outlook. The Integrated Care segment showed growth, while the BetterHelp segment faced a revenue decline. Adjusted EBITDA remained stable, reflecting the company's ongoing efforts to maintain financial performance amidst challenges.
Read more →-TDOC
Apr 15, 2026▲ +5.7%on this news· ran to +16% by day 3
Teladoc Health to Announce First Quarter 2026 Financial Results
Teladoc Health Inc. will announce its first quarter 2026 financial results on April 29, 2026, after market close. A conference call to discuss these results will take place at 5:00 p.m. ET on the same day. Participants can access the call via a dedicated phone line or through a live audio webcast.
Read more →-TDOC
Mar 30, 2026Teladoc Health Appoints Susan Salka, Experienced Healthcare Executive, to Its Board of Directors
Teladoc Health has appointed Susan Salka, former president and CEO of AMN Healthcare, to its board of directors, effective immediately. Salka is expected to bring valuable insights on care delivery transformation as the company pursues scalable health outcomes. She will serve on the board's audit and compensation committees. Her extensive experience in healthcare leadership, including a successful tenure at AMN Healthcare, positions her well to contribute to Teladoc's future growth.
Read more →-TDOC
Mar 3, 2026Teladoc Health to Participate in Upcoming Investor Conference
Teladoc Health, a leader in virtual care, announced that CEO Chuck Divita will participate in the Barclays 28th Annual Global Healthcare Conference on March 10, 2026. The event will be held in Miami at 1:00 p.m. ET, with a live audio webcast available for those interested. This participation highlights the company's commitment to virtual healthcare.
Read more →-TDOC
Feb 25, 2026Teladoc Health Reports Fourth Quarter and Full Year 2025 Results
Teladoc Health reported its financial results for the fourth quarter and full year 2025, revealing flat revenue for Q4 2025 compared to the previous year but a 2% decline for the full year. The company experienced a net loss of $25.1 million in Q4 2025, which was an improvement compared to the $48.4 million loss in the same quarter of 2024. Adjusted EBITDA rose by 12% year-over-year, indicating some operational progress. Despite these improvements, Teladoc faces challenges with a decline in overall revenue and specific segment performance, particularly in BetterHelp.
Read more →-TDOC
Feb 18, 2026Teladoc Health Appoints Michael Smith, Experienced Insurance and Financial Services Executive, to Its Board of Directors
Teladoc Health has appointed Michael Smith to its board of directors, following the retirements of Eric Evans and Thomas McKinley. Smith brings over 30 years of experience in financial management and strategic transformation, previously serving as Vice Chair and CFO of Voya Financial. He will contribute to the audit and nominating committees, expected to enhance Teladoc's strategic direction as it seeks long-term growth. The company will also announce its fourth-quarter 2025 results on February 25, 2026.
Read more →About Teladoc Health, Inc.
Headquarters155 E 44TH STREET, NEW YORK, NY, 10017
BIOPHARMAWATCH ELITE PLUS
Trade the next TDOC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime